NeuroMetrix Inc
NASDAQCM:NURO
United States / Healthcare / Healthcare Equipment & Supplies
Exchange Data
Hide this widget
Price
4.42 USD
Day change
-0.03 (-0.67%)
52-week range
2.66 - 4.73
19:59 - Closed
Summary of NeuroMetrix Inc
Hide this widget
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyz...
Price History
Chart Gallery
Hide this widget
1 Week
1 Month
3 Months
1 Year
5 Year
10 Years
- (-)
Data Explorer
Hide this widget
Data could not be retrieved
Peer Benchmarks
In the News
Hide this widget
Fair Value
Hide this widget
Average
4.55
Upside
3.0%
Uncertainty
HIGH
Spread
2.26 - 6.67
Market Range
52 weeks
$3
$5
$4.42
Analyst Targets
0 analysts
-
Investing Models
$2
$7
$4.55
Financial Health
Health Details
Hide this widget
Financial Health for NeuroMetrix is determined by ranking the company on over 100 factors against companies in the Healthcare sector and operating in Developed economic markets.
12345
Fair Performance
▼
▼
Financial Models for NeuroMetrix Inc
Model Gallery
Hide this widget
| 10Y DCF Revenue ExitView Updated 5 hours ago |
| 5Y DCF Revenue ExitView Updated 5 hours ago |
| DuPont ROE AnalysisView Updated 2 days ago |
| 10Y Historical FinancialsView Updated 2 days ago |
| 5Y Historical FinancialsView Updated 2 days ago |
| EV / EBIT MultiplesView Updated 5 hours ago |
| P/E MultiplesView Updated 5 hours ago |
| Price / Book MultiplesView Updated 5 hours ago |
| Price / Sales MultiplesView Updated 5 hours ago |
| EV / Revenue MultiplesView Updated 5 hours ago |
| 10Y DCF EBITDA ExitView Updated 5 hours ago |
| 10Y DCF Growth ExitView Updated 5 hours ago |
| 5Y DCF EBITDA ExitView Updated 5 hours ago |
| 5Y DCF Growth ExitView Updated 5 hours ago |
| Earnings Power ValueView Updated 5 hours ago |
| EV / EBITDA MultiplesView Updated 5 hours ago |
| CAPM WACC ModelView Updated 11 hours ago |
Historical Financials
Full Financials
Hide this widget
| (USD in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Sept-24 | Sept-23 | Sept-24 |
| Income Statement | |||||
| Revenue | 8.26 | 5.90 | 3.77 | 1.20 | 0.59 |
| Operating Income | (4.74) | (7.15) | (8.10) | (1.96) | (1.74) |
| Net Profit | (4.42) | (6.53) | (7.68) | (1.77) | (1.51) |
| Diluted EPS | -4.97 | -6.27 | -4.39 | -1.66 | -0.75 |
| EBITDA | (4.69) | (7.10) | (8.00) | (1.95) | (1.72) |
| Balance Sheet | |||||
| Cash & ST Invest. | 21 | 18 | 15 | 18 | 15 |
| Current Assets | 24 | 21 | 17 | 21 | 17 |
| Total Assets | 25 | 21 | 17 | 21 | 17 |
| Current Liabilities | 1.11 | 1.24 | 1.21 | 1.26 | 1.21 |
| Total Liabilities | 1.31 | 1.33 | 1.21 | 1.38 | 1.21 |
| Total Equity | 23 | 20 | 16 | 20 | 16 |
| Total Debt | 0.36 | 0.24 | 0.14 | 0.27 | 0.14 |
| Cash Flow Statement | |||||
| Cash Flow Operations | (5.29) | (6.08) | (6.69) | (2.06) | (1.79) |
| Cash From Investing | (17) | 1.16 | 3.05 | 1.66 | 1.11 |
| Cash From Financing | 3.86 | 2.33 | 3.10 | 0.00 | 0.00 |
| Free Cash Flow | (5.31) | (6.27) | (6.73) | (2.20) | (1.79) |
Analyst Notes
March 27, 2025
Hide this widget